Tags

Type your tag names separated by a space and hit enter

[Treatment of depressive disorder and comorbid personality pathology: combined therapy versus pharmacotherapy].
Tijdschr Psychiatr. 2007; 49(6):361-72.TP

Abstract

BACKGROUND

Comorbidity of depressive and personality disorder occurs frequently, in literature percentages of around 50 to nearly 80 percent are found. Also in the Mentrum depression study on which this article is grounded, high percentages of around 66% were found. There is no equivocal treatment method of choice in literature, and opinions differ as to whether personality pathology has an adverse influence on the efficacy of the treatment for depression.

AIM

To compare the results of pharmacotherapy and combined therapy in the treatment of depressive disorders in patients with and without comorbid personality disorder.

METHOD

A 6 month randomised clinical trial of antidepressants and combined therapy in ambulatory patients with major depressive disorder and a baseline score of at least 14 points on the 17-item Hamilton Rating Scale for Depression. Pharmacotherapy follows three subsequent steps in case of intolerance/inefficacy: fluoxetine, amitriptyline and moclobemide. In addition combination therapy includes 16 short-term sessions of psychodynamic supportive psychotherapy. Possible personality pathology is assessed by means of the 'Vragenlijst Kenmerken Persoonlijkheid' (a self report version of the International Personality Disorder Examination). Analyses of (co) variance and chi-squared tests were applied to assess the differences in both treatment conditions in the group with and without personality pathology.

RESULTS

Combined therapy was significantly more effective than pharmacotherapy for depressed patients with personality disorders. For depressed patients without personality disorders, combined therapy was not more effective than pharmacotherapy alone.

CONCLUSION

The combination of psychotherapy and pharmacotherapy seems to be the treatment of choice for depressed patients with comorbid personality pathology.

Authors+Show Affiliations

Mentrum GGZ Amsterdam, Polikliniek West, Frederik Hendrikstraat, Amsterdam. simone.kool@mentrum.nlNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article
Randomized Controlled Trial

Language

dut

PubMed ID

17611937

Citation

Kool, S, et al. "[Treatment of Depressive Disorder and Comorbid Personality Pathology: Combined Therapy Versus Pharmacotherapy]." Tijdschrift Voor Psychiatrie, vol. 49, no. 6, 2007, pp. 361-72.
Kool S, Schoevers R, Duijsens IJ, et al. [Treatment of depressive disorder and comorbid personality pathology: combined therapy versus pharmacotherapy]. Tijdschr Psychiatr. 2007;49(6):361-72.
Kool, S., Schoevers, R., Duijsens, I. J., Peen, J., van Aalst, G., de Jonghe, F., & Dekker, J. (2007). [Treatment of depressive disorder and comorbid personality pathology: combined therapy versus pharmacotherapy]. Tijdschrift Voor Psychiatrie, 49(6), 361-72.
Kool S, et al. [Treatment of Depressive Disorder and Comorbid Personality Pathology: Combined Therapy Versus Pharmacotherapy]. Tijdschr Psychiatr. 2007;49(6):361-72. PubMed PMID: 17611937.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Treatment of depressive disorder and comorbid personality pathology: combined therapy versus pharmacotherapy]. AU - Kool,S, AU - Schoevers,R, AU - Duijsens,I J, AU - Peen,J, AU - van Aalst,G, AU - de Jonghe,F, AU - Dekker,J, PY - 2007/7/6/pubmed PY - 2007/8/11/medline PY - 2007/7/6/entrez SP - 361 EP - 72 JF - Tijdschrift voor psychiatrie JO - Tijdschr Psychiatr VL - 49 IS - 6 N2 - BACKGROUND: Comorbidity of depressive and personality disorder occurs frequently, in literature percentages of around 50 to nearly 80 percent are found. Also in the Mentrum depression study on which this article is grounded, high percentages of around 66% were found. There is no equivocal treatment method of choice in literature, and opinions differ as to whether personality pathology has an adverse influence on the efficacy of the treatment for depression. AIM: To compare the results of pharmacotherapy and combined therapy in the treatment of depressive disorders in patients with and without comorbid personality disorder. METHOD: A 6 month randomised clinical trial of antidepressants and combined therapy in ambulatory patients with major depressive disorder and a baseline score of at least 14 points on the 17-item Hamilton Rating Scale for Depression. Pharmacotherapy follows three subsequent steps in case of intolerance/inefficacy: fluoxetine, amitriptyline and moclobemide. In addition combination therapy includes 16 short-term sessions of psychodynamic supportive psychotherapy. Possible personality pathology is assessed by means of the 'Vragenlijst Kenmerken Persoonlijkheid' (a self report version of the International Personality Disorder Examination). Analyses of (co) variance and chi-squared tests were applied to assess the differences in both treatment conditions in the group with and without personality pathology. RESULTS: Combined therapy was significantly more effective than pharmacotherapy for depressed patients with personality disorders. For depressed patients without personality disorders, combined therapy was not more effective than pharmacotherapy alone. CONCLUSION: The combination of psychotherapy and pharmacotherapy seems to be the treatment of choice for depressed patients with comorbid personality pathology. SN - 0303-7339 UR - https://www.unboundmedicine.com/medline/citation/17611937/[Treatment_of_depressive_disorder_and_comorbid_personality_pathology:_combined_therapy_versus_pharmacotherapy]_ L2 - http://www.tijdschriftvoorpsychiatrie.nl/en/tijdschrift/artikel/TVPart_1635 DB - PRIME DP - Unbound Medicine ER -